The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology,Pathology and Forensic Medicine
Link
http://www.nature.com/articles/labinvest201562.pdf
Reference48 articles.
1. Lahat G, Zhu Q-S, Huang K-L et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 2010;5:e10105.
2. Taylor BS, DeCarolis PL, Angeles CV et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov 2011;1:587–597.
3. Zhang P, Bill K, Liu J et al. MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling. Cancer Res 2012;72:1751–1762.
4. Hoffman A, Lazar AJ, Pollock RE et al. New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resist Updat 2011;14:52–66.
5. Singer S, Socci ND, Ambrosini G et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007;67:6626–6636.
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations;Molecular Cancer Therapeutics;2023-03-30
2. A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma;Clinical Cancer Research;2022-12-22
3. Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers;Frontiers in Oncology;2022-09-02
4. Ran GTPase is an independent prognostic marker in malignant melanoma which promotes tumour cell migration and invasion;Journal of Clinical Pathology;2020-11-24
5. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers;Investigational New Drugs;2020-03-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3